Mid-size pharma
Put capital behind the assets that earn it
Pharma portfolio prioritisation on comparable, approved cases for every asset, so stage gates, portfolio reviews and partnering choices rest on the same evidence and the same method.
What's at stake
"When every asset is argued differently, capital follows the loudest case, not the best one."
Compare assets on one method.
Portfolio views, a searchable asset register and approved valuations built the same way for every programme.
Faster, cleaner stage gates.
One governed case per asset that the functions have already agreed, instead of a new round of decks.
See competitive moves in your numbers.
Update the landscape or a profile and see the effect on differentiation, forecast and value across your assets.
- Evidence connectors for real-world evidence, research and market data
- Access from Microsoft 365 and Teams
- Hand-off of approved decisions to execution systems
- Signal alerts when the market moves
An illustrative 9-asset portfolio across 4 franchises, each asset with its own governed case.
Illustrative data
- NB-401Phase III$3.10B
- HX-201Phase II$2.15B
- IM-512Phase III$1.86B
- RS-330Phase II$1.24B
- IM-224Phase I$0.51B
- NB-207Phase I$0.42B
- RS-090Phase I$0.36B
- HX-118Preclinical$0.18B
- IM-031Preclinical$0.12B
FAQ
For mid-size pharma
Does it replace our portfolio management tool?
No. Keep your project system for resources and timelines. Pixen is where each asset's commercial case is built and approved.
Can each business unit have its own view?
Yes. Portfolio views and functional teams let each franchise work on its own assets while leadership compares them on one method.
How does it work with our existing data and tools?
Today you import population data with templates and export approved cases to Excel and PDF. Keep your research and data tools for inputs; Pixen turns their output into the case.